Lymphocyte deficiency limits Epstein-Barr virus latent membrane protein 1 induced chronic inflammation and carcinogenic pathology in vivo

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Hannigan, Adele ^a,b   Qureshi, Asif M ^a   Nixon, Colin ^c   Tsimbouri, Penelope M ^a   Jones, Sarah ^a   Philbey, Adrian W ^a   Wilson, Joanna B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Engeneic Ltd   (Australia)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CD30 LIGAND; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL1 CHEMOKINE; CXCL13 CHEMOKINE; CXCL2 CHEMOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 3; L SELECTIN; LATENT MEMBRANE PROTEIN 1; LEPTIN; NATURAL KILLER CELL RECEPTOR NKG2D; RANTES; SOMATOMEDIN BINDING PROTEIN 5; STAT3 PROTEIN; THROMBOCYTE FACTOR 4; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; CHEMOKINE; CYTOKINE; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; HOMEODOMAIN PROTEIN; MATRIX PROTEIN; RAG 1 PROTEIN; RAG-1 PROTEIN; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MIGRATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DERMATITIS; FEMALE; IN VIVO STUDY; LEUKOCYTE; MAST CELL; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; CELL MOTION; CELL TRANSFORMATION; EPSTEIN BARR VIRUS; GENETICS; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; PATHOLOGY; SKIN; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; VIROLOGY;

HUMAN HERPESVIRUS 4; MURINAE; MUS MUSCULUS;

ANIMALS; B-LYMPHOCYTE SUBSETS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINES; CYTOKINES; FEMALE; HERPESVIRUS 4, HUMAN; HOMEODOMAIN PROTEINS; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SKIN; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; VIRAL MATRIX PROTEINS;

EID: 79551520666     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-11     Document Type: Article

References (75)

1. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004, 4:688-694. 10.1038/nrc1433, 15343275.
2. Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006, 42:708-716. 10.1016/j.ejca.2006.01.020, 16556496.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687. 10.1038/nrc1934, 16929323.
4. Yan L, Anderson GM, DeWitte M, Nakada MT. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 2006, 42:793-802. 10.1016/j.ejca.2006.01.013, 16524718.
5. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7:411-423. 10.1016/j.ccr.2005.04.014, 15894262.
6. Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006, 42:760-767. 10.1016/j.ejca.2006.01.002, 16510278.
7. Zong YS, Lin H, Choy DT, Sham JS, Wei W, Chan KH, Ng MH. Nasopharyngeal carcinoma and lymphoinfiltration. Oncology 1991, 48:290-296. 10.1159/000226945, 1891170.
8. Tang KF, Tan SY, Chan SH, Chong SM, Loh KS, Tan LK, Hu H. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum Pathol 2001, 32:42-49. 10.1053/hupa.2001.20886, 11172294.
9. Hu H, Tang KF, Chua YN, Lu J, Feng P, Chew CT, Chan SH. Expression of interleukin-18 by nasopharyngeal carcinoma cells: a factor that possibly initiates the massive leukocyte infiltration. Hum Pathol 2004, 35:722-728. 10.1016/j.humpath.2004.01.026, 15188138.
10. Kneile JR, Tan G, Suster S, Wakely PE. Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma. Histopathology 2006, 48:855-861. 10.1111/j.1365-2559.2006.02449.x, 16722935.
11. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M, Young LS. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 1997, 14:2899-2916. 10.1038/sj.onc.1201258, 9205097.
12. Li J, Zhang XS, Xie D, Deng HX, Gao YF, Chen QY, Huang WL, Masucci MG, Zeng YX. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression. Cancer Biol Ther 2007, 6:1997-2004. 10.4161/cbt.6.12.5160, 18087217.
13. Yoshizaki T, Horikawa T, Qing-Chun R, Wakisaka N, Takeshita H, Sheen TS, Lee SY, Sato H, Furukawa M. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res 2001, 7:1946-1951.
14. Buettner M, Meyer B, Schreck S, Niedobitek G. Expression of RANTES and MCP-1 in epithelial cells is regulated via LMP1 and CD40. Int J Cancer 2007, 121:2703-2710. 10.1002/ijc.23018, 17721998.
15. Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 2007, 120:2401-2410. 10.1002/ijc.22334, 17315195.
16. Morris MA, Dawson CW, Wei W, O'Neil JD, Stewart SE, Jia J, Bell AI, Young LS, Arrand JR. Epstein-Barr virus-encoded LMP1 induces a hyperproliferative and inflammatory gene expression programme in cultured keratinocytes. J Gen Virol 2008, 89:2806-2820. 10.1099/vir.0.2008/003970-0, 18931079.
17. Ikeda O, Sekine Y, Mizushima A, Oritani K, Yasui T, Fujimuro M, Muromoto R, Nanbo A, Matsuda T. BS69 negatively regulates the canonical NF-kappaB activation induced by Epstein-Barr virus-derived LMP1. FEBS Lett 2009, 583:1567-1574. 10.1016/j.febslet.2009.04.022, 19379743.
18. Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991, 266:7313-7316.
19. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759. 10.1038/nri1703, 16175180.
20. Stevenson D, Charalambous C, Wilson JB. Epstein-Barr Virus Latent Membrane Protein 1 (CAO) Up-regulates VEGF and TGFα Concomitant with Hyperlasia, with Subsequent Up-regulation of p16 and MMP9. Cancer Res 2005, 65:8826-8835. 10.1158/0008-5472.CAN-05-0591, 16204053.
21. Charalambous CT, Hannigan A, Tsimbouri P, McPhee GM, Wilson JB. Latent membrane protein 1-induced EGFR signalling is negatively regulated by TGF alpha prior to neoplasia. Carcinogenesis 2007, 28:1839-1848. 10.1093/carcin/bgm055, 17361012.
22. Ford AL, Foulcher E, Goodsall AL, Sedgwick JD. Tissue digestion with dispase substantially reduces lymphocyte and macrophage cell-surface antigen expression. J Immunol Methods 1996, 194:71-75. 10.1016/0022-1759(96)00067-1, 8690942.
23. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005, 6:928-937. 10.1038/ni1239, 16116470.
24. Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease. Arthritis Res Ther 2003, 5(Suppl 4):S17-21. 10.1186/ar1007, 2833439, 15180893.
25. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37. 10.1038/nrc1782, 16397525.
26. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 1994, 57:240-244. 10.1002/ijc.2910570218, 8157362.
27. Vockerodt M, Haier B, Buttgereit P, Tesch H, Kube D. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 2001, 280:183-198. 10.1006/viro.2000.0768, 11162833.
28. McColl SR, Roberge CJ, Larochelle B, Gosselin J. EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 α in human neutrophils. J Immunol 1997, 159:6164-6168.
29. Hol J, Wilhelmsen L, Haraldsen G. The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies. J Leukoc Biol 2009, 87:501-508. 10.1189/jlb.0809532, 20007247.
30. Yoshimoto T, Nagase H, Yoneto T, Inoue J, Nariuchi H. Interleukin-12 expression in B cells by transformation with Epstein-Barr virus. Biochem Biophys Res Commun 1998, 252:556-560. 10.1006/bbrc.1998.9693, 9837745.
31. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809. 10.1038/nrc2734, 19851315.
32. Maritano D, Sugrue ML, Tininini S, Dewilde S, Strobl B, Fu X, Murray-Tait V, Chiarle R, Poli V. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol 2004, 5:401-409. 10.1038/ni1052, 15021879.
33. Hannigan A, Burchmore R, Wilson JB. The optimization of protocols for proteome difference gel electrophoresis (DiGE) analysis of preneoplastic skin. J Proteome Res 2007, 6:3422-3432. 10.1021/pr0606878, 17696380.
34. Yu Y, Dong W, Zhou X, Li S. The significance of serum soluble intercellular adhesion molecule 1 and transforming growth factor alpha in patients with nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130:1205-1208. 10.1001/archotol.130.10.1205, 15492170.
35. Miller WE, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J Virol 1997, 71:586-594. 191088, 8985387.
36. Tao YG, Tan YN, Liu YP, Song X, Zeng L, Gu HH, Tang M, Li W, Yi W, Cao Y. Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner. Cell Signal 2004, 16:781-790. 10.1016/j.cellsig.2003.12.001, 15115657.
37. Kung CP, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J Virol 2008, 82:5486-5493. 10.1128/JVI.00125-08, 2395195, 18367518.
38. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 2009, 100:134-144. 10.1038/sj.bjc.6604794, 2634691, 19088723.
39. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY, Hung MC. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005, 7:575-589. 10.1016/j.ccr.2005.05.007, 15950906.
40. Huang Y, Qiu J, Dong S, Redell MS, Poli V, Mancini MA, Tweardy DJ. Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. J Biol Chem 2007, 282:34958-34967. 10.1074/jbc.M704548200, 17855361.
41. Fischer M, Harvima IT, Carvalho RF, Moller C, Naukkarinen A, Enblad G, Nilsson G. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006, 116:2748-2756. 10.1172/JCI24274, 1560346, 16964309.
42. Rudolph P, Lappe T, Schmidt D. Expression of CD30 and nerve growth factor-receptor in neoplastic and reactive vascular lesions: an immunohistochemical study. Histopathology 1993, 23:173-178. 10.1111/j.1365-2559.1993.tb00476.x, 8406390.
43. Visco C, Nadali G, Vassilakopoulos TP, Bonfante V, Viviani S, Gianni AM, Federico M, Luminari S, Peethambaram P, Witzig TE, et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006, 77:387-394. 10.1111/j.1600-0609.2006.00725.x, 16879607.
44. Zhang M, Yao Z, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Janik J, Brechbiel MW, Waldmann TA. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood 2006, 108:705-710. 10.1182/blood-2005-11-4607, 1895489, 16551968.
45. Polte T, Behrendt AK, Hansen G. Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol 2006, 118:942-948. 10.1016/j.jaci.2006.07.014, 17030250.
46. Weinreb I, Bailey D, Battaglia D, Kennedy M, Perez-Ordonez B. CD30 and Epstein-Barr virus RNA expression in sclerosing angiomatoid nodular transformation of spleen. Virchows Arch 2007, 451:73-79. 10.1007/s00428-007-0422-7, 17492312.
47. Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 2009, 647:174-185. full_text, 19760074.
48. Carvalho RF, Ulfgren AK, Engstrom M, Klint E, Nilsson G. CD153 in rheumatoid arthritis: detection of a soluble form in serum and synovial fluid, and expression by mast cells in the rheumatic synovium. J Rheumatol 2009, 36:501-507. 10.3899/jrheum.080288, 19208589.
49. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX, Medeiros LJ. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 2005, 18:1365-1370. 10.1038/modpathol.3800419, 1382062, 15920551.
50. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME, Abraham LJ, Watanabe T, Horie R. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 2005, 65:7628-7634.
51. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991, 146:1410-1415.
52. Shimada Y, Hasegawa M, Kaburagi Y, Hamaguchi Y, Komura K, Saito E, Takehara K, Steeber DA, Tedder TF, Sato S. L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. J Immunol 2003, 170:4325-4334.
53. Rossi B, Constantin G. Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm Allergy Drug Targets 2008, 7:85-93. 10.2174/187152808785107633, 18691137.
54. Kirshenbaum AS, Goff JP, Dreskin SC, Irani AM, Schwartz LB, Metcalfe DD. IL-3-dependent growth of basophil-like cells and mastlike cells from human bone marrow. J Immunol 1989, 142:2424-2429.
55. Kohno M, Yamasaki S, Tybulewicz VL, Saito T. Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood 2005, 105:2059-2065. 10.1182/blood-2004-07-2639, 15542585.
56. Yao L, Pike SE, Pittaluga S, Cherney B, Gupta G, Jaffe ES, Tosato G. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 2002, 51:358-366. 10.1007/s00262-002-0294-2, 12192535.
57. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev 2009, 8:379-383. 10.1016/j.autrev.2008.12.002, 19105984.
58. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol 2009, 27:22-27.
59. Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV, Guidotti LG. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001, 194:1755-1766. 10.1084/jem.194.12.1755, 2193580, 11748277.
60. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, Dinarello CA, Paul WE. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 2009, 106:7119-7124. 10.1073/pnas.0902745106, 2678417, 19359475.
61. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: a key inflammatory mediator in psoriasis?. Cytokine 2006, 33:72-78. 10.1016/j.cyto.2005.12.001, 16460958.
62. Groves RW, Mizutani H, Kieffer JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. Proc Natl Acad Sci USA 1995, 92:11874-11878. 10.1073/pnas.92.25.11874, 40505, 8524866.
63. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, Kanaly ST, Towne JE, Willis CR, Kuechle MK, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 2007, 204:2603-2614. 10.1084/jem.20070157, 2118475, 17908936.
64. Singh AK, Mao C, Lebedeva TV. In vitro role of IL-1 in heightened IgG, anti-DNA, and nephritogenic idiotype production by B cells derived from the murine MRL/lpr lupus model. Clin Immunol Immunopathol 1994, 72:410-415. 10.1006/clin.1994.1161, 8062453.
65. Klein SC, Kube D, Abts H, Diehl V, Tesch H. Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection. Leuk Res 1996, 20:633-636. 10.1016/0145-2126(96)00029-X, 8913315.
66. Beck A, Pazolt D, Grabenbauer GG, Nicholls JM, Herbst H, Young LS, Niedobitek G. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease. J Pathol 2001, 194:145-151. 10.1002/path.867, 11400141.
67. Ohtsuka Y, Lee J, Stamm DS, Sanderson IR. MIP-2 secreted by epithelial cells increases neutrophil and lymphocyte recruitment in the mouse intestine. Gut 2001, 49:526-533. 10.1136/gut.49.4.526, 1728474, 11559650.
68. Berzofsky JA, Terabe M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol Immunother 2008, 57(11):1679-83. 10.1007/s00262-008-0495-4, 18369622.
69. Horwitz DA, Zheng SG, Wang J, Gray JD. Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3+CD4+ Treg. Eur J Immunol 2008, 38:912-915. 10.1002/eji.200738109, 18395858.
70. Davidson TS, DiPaolo RJ, Andersson J, Shevach EM. Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol 2007, 178:4022-4026.
71. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006, 177:896-904.
72. Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ, Bloemena E, Middeldorp JM. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 2000, 165:663-670.
73. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003, 170:6183-6189.
74. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992, 68:869-877. 10.1016/0092-8674(92)90030-G, 1547488.
75. Macdiarmid J, Stevenson D, Campbell DH, Wilson JB. The latent membrane protein 1 of Epstein-Barr virus and loss of the INK4a locus: paradoxes resolve to cooperation in carcinogenesis in vivo. Carcinogenesis 2003, 24:1209-1218. 10.1093/carcin/bgg070, 12807717.